MALT1 inhibition is efficacious in both naïve and ibrutinib-resistant chronic lymphocytic leukemia

The clinical efficacy displayed by ibrutinib in chronic lymphocytic leukemia (CLL) has been challenged by the frequent emergence of resistant clones. The ibrutinib target, Bruton's tyrosine kinase (BTK), is essential for B cell receptor signaling, and most resistant cases carry mutations in BTK...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Res
Hauptverfasser: Saba, Nakhle S., Wong, Deanna H., Tanios, Georges, Iyer, Jessica R., Lobelle-Rich, Patricia, Dadashian, Eman L., Liu, Delong, Fontan, Lorena, Flemington, Erik K., Nichols, Cydney M., Underbayev, Chingiz, Safah, Hana, Melnick, Ari, Wiestner, Adrian, Herman, Sarah E. M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2017
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5732856/
https://ncbi.nlm.nih.gov/pubmed/28993409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-2485
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge